

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Daniel P. Becker, et al.
Serial No: 10/722,104
Filed: November 25, 2003
For: Heteroarylsulfonylmethyl Hydroxamic Acids and Amides and Their Use
as Protease Inhibitors
Confirmation No: 6396
Group Art Unit: 1614
Examiner: TBA
Attorney Ref: 01414/1/US
Pfizer Ref: 27788/USA
HDP Ref: 6794-000080/US

January 31, 2005

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam/Sir:

To comply with 37 CFR §1.97 and §1.98, Applicants submit the enclosed Form PTO-1449.

In accordance with MPEP §609 and §707.05(b), Applicants respectfully request that each document listed be given thorough consideration, and that the Examiner cite each document of record in the prosecution history of the present application by initialing the Form PTO-1449 next to each document. Applicants request such initialing even if the Examiner does not consider: (1) a document to be sufficiently pertinent to use in a rejection; (2) a document to be prior art for any reason; or (3) that the guidelines for citation have been fully complied with respecting a particular document. Applicants make this request so that each document becomes cited on the face of a patent issuing on the present application.

Applicants submit this information disclosure statement in compliance with the duty to disclose information material to patentability under 37 CFR §1.56, but by listing such documents are not admitting that such documents are necessarily relevant or prior art. Applicants intend no representation that the listed documents represent the results of a complete search. Applicants anticipate that the Examiner, in the normal course of examination, will make an independent

search consistent with 37 CFR §1.104, and, in the course of such search, will review for relevance every document listed on the attached form even if not initialed.


Some references cited in this information disclosure statement are U.S. patents or U.S. patent application publications. Copies of those references are therefore not being provided in accordance with 37 C.F.R. §1.98(a)(2)(i) and MPEP §609 Part III(A)(2). Applicants, however, will provide copies of such references upon request from the Examiner.

Applicants request early and favorable consideration of this patent application.

* * * * *

Applicants believe that they do not owe any fee in connection with this information disclosure statement. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **08-0750**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or §1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **08-0750**.

Respectfully submitted,



David M. Gryte, PTO Reg. No. 41,809
Harness, Dickey & Pierce
7700 Bonhomme, Suite 400
St. Louis, Missouri 63105
(314) 726-7500 (tel)
(314) 726-7501 (fax)

Information Disclosure Statement
Appl. No. 10/722,104
January 31, 2005

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service on **January 31, 2005** with sufficient postage as first class mail (including Express Mail per MPEP § 512), and addressed to **Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.**



DMG/JPG/PML
enclosures

**TRANSMITTAL
FORM**


(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/722,104	
	Filing Date	November 25, 2003	
	First Named Inventor	Daniel P. Becker, et al	
	Art Unit	1614	
	Examiner Name	TBA	
Total Number of Pages in This Submission		Attorney Docket Number	01414/1/US (Pfizer Ref: 27788/USA)

ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) ____	<input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO-1449; 18 References; Return Receipt Postcard
<div style="border: 1px solid black; padding: 5px; width: fit-content;">Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Harness, Dickey & Pierce, P.L.C.	Attorney Name	David M. Gryte	Reg. No.	41,809
Signature					
Date	January 31, 2005				

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	David M. Gryte	Express Mail Label No.	EV 327048787 US
Signature		Date	January 31, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**
(Use several sheets if necessary)

Sheet 1 of 3

ATTORNEY DOCKET NO.

SERIAL NO.

01414/1/US (Pfizer Ref. 27788A/USA)

10/722,104

APPLICANT

Daniel P. Becker, et al.

FILING DATE

GROUP

11/25/2003

1614

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	Filing Date
1.		4,595,700	6/17/86	Donald et al.	514/616	2/21/85
2.		6,013,649	1/11/00	Freskos et al.	514/237.8	7/22/97
3.		6,300,514	10/9/01	Takahashi et al.	549/462	1/15/99
4.		6,448,250	9/10/02	DeCrescenzo et al.	546/252	2/7/00
5. (office action and notices of allowances enclosed)		6,541,489, including the 12/17/01 Office action, 5/16/02 notice of allowance, and 11/8/02 notice of allowance	4/1/03	Barta et al.	514/330	7/31/00
6.		6,683,093	1/27/04	Barta et al.	514/316	11/21/01
7. (Office action and notice of allowance enclosed)		6,750,233, including 11/18/02 Office action and 5/9/03 notice of allowance	11/28/02	Barta et al.	514/336	9/17/01
8. (allowed claims and notice of allowance enclosed)		Publ. No. 2004-0048852 (Appl. No. 10/337,942), including allowed claims and 2/13/04 notice of allowance	3/11/04	Barta et al.	514/317	1/7/03
9. (enclosed)		Abandoned Appl. No. 09/311,837, including 6/14/00 Office action, 5/3/01 Office action, 11/20/03 Office action, and 7/28/04 Office action		Barta et al.		5/14/99
10. (Office actions enclosed)		Abandoned Appl. Publ. No. 20010039287 (Appl. No. 09/256,948), including 6/1/00 Office action and 3/29/01 Office action		Barta et al.	514/330	2/24/99

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

57

FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**
(Use several sheets if necessary)

Sheet 2 of 3

ATTORNEY DOCKET NO.

01414/1/US (Pfizer Ref.
27788A/USA)

SERIAL NO.

10/722,104

APPLICANT

Daniel P. Becker, et al.

FILING DATE

11/25/2003

GROUP

1614

11. (Office actions enclosed)		Abandoned Appl. Publ. No. 20010014688 (Appl. No. 09/191,129), including 12/29/99 Office action, 8/7/00 Office action, 2/16/01 Office action, 11/26/01 Office action, and 6/25/02 Office action		Barta et al.	514/318	11/13/98
12. (enclosed)		Abandoned Appl. No. 09/186,410, including 11/19/99 Office action		Barta et al.		11/13/98

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
13.		WO 90/05719	05/31/90	PCT	C07C 323/62		
14.		WO 93/20047	10/14/93	PCT	C07C 317/44		
15.		WO 94/02466	02/03/94	PCT	C07D 221/14		
16.		WO 94/24140	10/27/94	PCT	C07H 13/04		
17.		WO 95/09841	4/13/95	PCT	C07C 323/60		
18.		WO 95/13289	5/11/95	PCT	A61K 9/127		
19.		WO 95/29892	11/9/95	PCT	C07D 207/327		
20.		WO 96/06074	2/29/96	PCT	C07C 259/06		
21.		WO 96/11209	4/18/96	PCT	C07K 5/06		
22.		WO 97/20824	6/12/97	PCT	C07D 241/04		
23.		WO 97/24117	7/10/97	PCT	A61K 31/19		

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p> <p>Sheet 3 of 3</p>	<p>ATTORNEY DOCKET NO.</p> <p>01414/1/US (Pfizer Ref. 27788A/USA)</p>	<p>SERIAL NO.</p> <p>10/722,104</p>
	<p>APPLICANT</p>	
	<p>Daniel P. Becker, et al.</p>	
	<p>FILING DATE</p> <p>11/25/2003</p>	<p>GROUP</p> <p>1614</p>

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.